CH EMED EPR
1.0.0 - trial-use Switzerland flag

This page is part of the FHIR eMedication exchange formats for the implementation effort of CARA within its EPR community (v1.0.0: STU1) based on FHIR (HL7® FHIR® Standard) R4. This is the current published version. For a full list of available versions, see the Directory of published versions

Table of Contents

.. 0 Table of Contents
... 1 Home
... 2 Changelog
... 3 Document Dis
... 4 Document Mtp
... 5 Document Padv
... 6 Document Pml
... 7 Document Pmlc
... 8 Document Pre
... 9 Guidance Amount Quantity
... 10 Guidance Compositions
... 11 Guidance Datatypes
... 12 Guidance Index
... 13 Guidance Others
... 14 Guidance Treatment
... 15 Use Case
... 16 Workflow
... 17 Artifacts Summary
.... 17.1 Body Weight Observation
.... 17.2 CH EMED EPR Device
.... 17.3 CH EMED EPR Medication
.... 17.4 CH EMED EPR Medication (DIS)
.... 17.5 CH EMED EPR Organization
.... 17.6 CH EMED EPR Patient
.... 17.7 CH EMED EPR Practitioner
.... 17.8 CH EMED EPR PractitionerRole
.... 17.9 CH EMED EPR RelatedPerson
.... 17.10 DIS Composition
.... 17.11 DIS Document
.... 17.12 DIS MedicationDispense
.... 17.13 MTP Composition
.... 17.14 MTP Document
.... 17.15 MTP MedicationStatement
.... 17.16 PADV Changed MedicationRequest
.... 17.17 PADV Changed MedicationStatement
.... 17.18 PADV Composition
.... 17.19 PADV Document
.... 17.20 PADV Observation
.... 17.21 PML Composition
.... 17.22 PML Document
.... 17.23 PML MedicationDispense
.... 17.24 PML MedicationRequest
.... 17.25 PML MedicationStatement
.... 17.26 PML Observation
.... 17.27 PMLC Composition
.... 17.28 PMLC Document
.... 17.29 PMLC MedicationStatement
.... 17.30 PRE Composition
.... 17.31 PRE Document
.... 17.32 PRE MedicationRequest
.... 17.33 Amount Quantity
.... 17.34 Amount Range
.... 17.35 Dosage (MedicationRequest)
.... 17.36 Dosage (MedicationStatement / MedicationDispense)
.... 17.37 Dosage Split
.... 17.38 Ratio (Amount / Amount)
.... 17.39 Ratio (Amount / Time)
.... 17.40 Time Quantity
.... 17.41 Amount Quantity Unit Codes
.... 17.42 Event Timings
.... 17.43 Route of Administration
.... 17.44 Substance Administration Substitution Codes
.... 17.45 Time Quantity Unit Codes
.... 17.46 Bundle: DIS 1
.... 17.47 Bundle: MTP 1
.... 17.48 Bundle: MTP Dafalgan Effervescent CARAPMP004
.... 17.49 Bundle: MTP Paracetamol CARAPMP004
.... 17.50 Bundle: PADV 1
.... 17.51 Bundle: PADV 2
.... 17.52 Bundle: PADV CANCEL paracetamol Axapharm
.... 17.53 Bundle: PML #1
.... 17.54 Bundle: PMLC document with a prescribed axapharm paracetamol treatment
.... 17.55 Bundle: PMLC document with a prescribed dafalgan effervescent paracetamol treatment
.... 17.56 Bundle: PMLC #1
.... 17.57 Bundle: PRE 1
.... 17.58 Bundle: PRE Dafalgan eff 500mg
.... 17.59 Bundle: PRE Paracetamol Axapharm 1g
.... 17.60 Bundle: use case PML #1
.... 17.61 Changed Medication Statement: Triatec (PADV)
.... 17.62 Composition for PMLC document with a prescribed dafalgan effervescent paracetamol treatment
.... 17.63 Composition: PMLC document with a prescribed axapharm paracetamol treatment
.... 17.64 Composition: use case PML #1
.... 17.65 Device: PMP Aggregator
.... 17.66 Medication: Triatec
.... 17.67 MedicationDispense: Triatec (DIS)
.... 17.68 MedicationDispense: Triatec (PML)
.... 17.69 MedicationNorvasc
.... 17.70 MedicationParacetamolAxapharm
.... 17.71 MedicationParacetamolDafalganEff
.... 17.72 MedicationRamipril
.... 17.73 MedicationRequest: Dafalgan effervescent 500mg (PRE)
.... 17.74 MedicationRequest: Paracetamol Axapharm 1g (PRE)
.... 17.75 MedicationRequest: Triatec (PML)
.... 17.76 MedicationRequest: Triatec (PRE)
.... 17.77 MedicationStatement: Paracetamol Axapharm (MTP)
.... 17.78 MedicationStatement: Paracetamol Axapharm (PMLC)
.... 17.79 MedicationStatement: Paracetamol Dafalgan Effervescent (MTP)
.... 17.80 MedicationStatement: Paracetamol Dafalgan Effervescent (PMLC)
.... 17.81 MedicationStatement: Triatec (MTP)
.... 17.82 MedicationWithATC
.... 17.83 MedicationWithTwoIngredients
.... 17.84 Observation: CANCEL of Axapharm paracetamol treatment.
.... 17.85 Observation: Ramipril (PADV)
.... 17.86 Observation: Triatec (PADV)
.... 17.87 Observation: Triatec (PML)
.... 17.88 Organization: CARA
.... 17.89 Organization: HUG
.... 17.90 Patient: Dupont
.... 17.91 Patient: Michaël Christopher KARCE
.... 17.92 Practitioner: Perry Cox
.... 17.93 PractitionerRole: Perry Cox @ HUG